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Duchenne muscular dystrophy (DMD) is one of the most common lethal, hereditary diseases of childhood. Since the identification of the
genetic basis of this disorder, there has been the hope that a cure would be developed in the form of gene therapy. This has yet to be realized, but
many different gene therapy approaches have seen dramatic advances in recent years. Although viral-mediated gene therapy has been at the
forefront of the field, several non-viral gene therapy approaches have been applied to animal and cellular models of DMD. These include plasmid-
mediated gene delivery, antisense-mediated exon skipping, and oligonucleotide-mediated gene editing. In the past several years, non-viral gene
therapy has moved from the laboratory to the clinic. Advances in vector design, formulation, and delivery are likely to lead to even more rapid
advances in the coming decade. Given the relative simplicity, safety, and cost-effectiveness of these methodologies, non-viral gene therapy
continues to have great promise for future gene therapy approaches to the treatment of DMD.
Published by Elsevier B.V.Keywords: Muscular dystrophy; Dystrophin; Antisense oligonucleotide; Plasmid gene therapy; Gene editing1. Introduction
Duchenne muscular dystrophy (DMD) is a devastating
disorder of childhood, leading to loss of ambulation during the
first decade of life, progressive weakness, and death usually in
the twenties [1]. The molecular basis of this disease is an
absence of the dystrophin protein [2]. At the genetic level,
dystrophin deficiency arises from mutations in the dystrophin
gene, but the range of mutations is enormous both in terms of
types of mutations (deletions, duplications, inversions, point
mutations) and in terms of the location of the mutation along the
2.5 Mb dystrophin gene [3,4]. Despite the advances in
molecular diagnoses, accepted treatment modalities remainAbbreviations: AON, antisense oligonucleotide; BMD, Becker muscular
dystrophy; DMD, Duchenne muscular dystrophy; ODN, oligodeoxynucleo-
tides; RDO, RNA/DNA chimeric oligonucleotide
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doi:10.1016/j.bbadis.2006.07.009limited to corticosteroids and physiotherapy, and treatment is
largely supportive [1,5].
Experimental approaches for the treatment of DMD have
greatly expanded in the past decade. Gene and cell therapies
continue to be at the forefront of those approaches, but
pharmacologic and hybrid methods have received considerable
attention [5]. Traditionally, gene therapy has been divided into
viral and non-viral, although this distinction also can be blurred
as technologies are combined. Within the category of non-viral
gene therapy methodologies, three different approaches have
been pursued with respect to DMD. These are: 1) the use of
plasmid DNA to deliver dystrophin cDNA constructs; 2) the use
of antisense oligonucleotides (AONs) to induce exon skipping
of the dystrophin pre-mRNA to convert and out-of-frame
transcript to an in-frame transcript; and 3) the use of RNA–DNA
chimeric oligonucleotides (RDOs) or oligodeoxynucleotides
(ODNs) for genome editing or gene correction to alter single
bases in the dystrophin gene to correct point mutations or to alter
mRNA splicing. Reviews of the each of these technologies have
been published in manuscript and chapter form [6–10]. The
focus of this review is to summarize the most recent
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the most promising and important research directions, to
enumerate specific hurdles and challenges faced by each
technology, and to discuss the status of nascent clinical trials
in humans.
Although plasmid-mediated gene delivery, AON-induced
exon skipping, and oligonucleotide-mediated genome editing
have unique promises and challenges (Table 1 and as described
below), there are also commonalities in terms of advantages
and disadvantages when compared to viral-mediated gene
therapy approaches. In general, given current technologies, it is
considered that non-viral vectors will represent a less expensive
and safer mode of therapy. The cost of production of plasmids
and oligonucleotides has dramatically fallen in the past decade,
whereas the generation of clinical grade viral stocks has
inherently high costs. Many safety issues remain to be
determined for all forms of gene therapy, but concerns over
potential adverse effects of viral-mediated gene therapy have
been realized in terms of morbidity and mortality in human
clinical trials [11,12]. Despite the theoretical advantages of
non-viral vectors in terms of safety, caution will be warranted
as these approaches also move from laboratory animals to
humans.
Perhaps the most obvious and important disadvantage of
non-viral vectors is one of delivery, and here delivery is meant
to include everything from the distribution via the circulation of
the therapeutic vector to all skeletal muscles and the heart, the
process by which the vectors leave the blood to reach muscleTable 1
Plasmid-mediated
gene delivery
Antisense-induced
exon skipping
Oligonucleotide-
mediated
gene editing
Efficiency
of inducing
dystrophin
expression a
+++ +++ +
Duration of effect b +++ + ++++
Uptake of vector
after delivery
to tissue c
++ ++++ ++++
Applicability
regardless of
mutation d
++++ ++ +
a Efficiency is a difficult parameter to compare because measures of efficiency
vary widely. Based on in vivo type experiments in which the primary outcome is
the generation of dystrophin-positive fibers, both plasmid-mediated gene
delivery and AON-induced exon skipping yield much higher numbers than
oligonucleotide-mediated gene editing. Of course, none of these measures are
normalized to vector number or concentration in the cell.
b AON-induced exon skipping results in transient dystrophin expression,
plasmid-mediated gene delivery results on sustained dystrophin expression, and
oligonucleotide-mediated gene editing results in permanent correction.
c In general, the smaller oligonucleotides used for exon skipping and gene
editing are more readily taken up into muscle fibers that are large plasmids, even
when plasmids are formulated with agents to enhance uptake.
d The expression of dystrophin from a plasmid is an effective treatment
regardless of the nature of the endogenous gene mutation. By contrast, both
AON-induced exon skipping and oligonucleotide-mediated gene editing require
vectors specifically designed for the underlying mutation. However, certain
AONs will be applicable to a number of different deletion mutations.cells, the mechanisms by which the vectors enter the cells, and
finally the processes by which the vectors reach the intracellular
target. Although non-viral vector development can improve
upon the specificity and efficiency of these phases of delivery,
viruses accomplish all of these aspects of delivery without any
help from the investigator. As such, important recent develop-
ments that could apply to many or all non-viral approaches for
DMD include advances in intra-arterial and intravenous
delivery protocols [13–17], adjunct treatments to promote
vascular permeability to facilitate the transfer of vectors
(including viral vectors) from the circulation to the tissue bed
[18–20], and formulations to enhance stability and cellular
uptake of non-viral vectors [21–23]. Although some of the most
promising results have been obtained by intra-arterial injections,
and even though multiple arterial injections to reach a larger
subset of muscles of a patient would be a viable approach,
having an intravenous deliver system would be far less invasive.
Clearly immunological challenges are faced by all gene
therapy approaches. The possibility of an immune response
directed against the therapeutic protein is always a concern
when the individual is deficient for that protein. In the case of
dystrophin, both humoral and cellular immune responses have
been detected in dystrophin-deficient mdx mice following
delivery of full-length dystrophin cDNAs, although not
following the delivery of a minidystrophin construct [24,25].
This suggests that the response in an individual patient might
depend on the specific epitopes in the protein expressed, either
from an exogenous cDNA or from modulation of the
endogenous gene or transcript. Studies of plasmid-mediated
gene expression indicate that the likelihood of developing
immune responses against the novel protein may be ameliorated
by using muscle-specific promoters, and that even transient
immunosuppression around the time of plasmid delivery can
limit the development of an immune response [26].
The other major immunological issue is of course the
possibility of an immune response against the vector itself.
Although certainly safer than viral vectors in this regard, non-
viral gene therapy vectors still have the potential to induce
immune responses, particularly if they contain bacterial DNA
sequences with unmethylated CpG motifs [27]. Although
intramuscular injections of plasmid or double-stranded oligo-
nucleotides bearing such sequences may result in local
inflammatory responses [28], and repeated injections of
plasmid have been shown to result in increases in circulating
levels of anti-DNA antibodies [29], there have been no reports
of autoimmune diseases resulting from such treatments.
Whether low levels of circulating anti-DNA antibodies
generated by treatment with non-viral vectors could attenuate
subsequent systemic treatments with those vectors remains to
be determined.
Finally, there is one other unknown that haunts the field of
gene therapy for DMD, and that is the uncertainty of the normal
turnover rate for myonuclei. Estimates of myonuclear turnover
rate have been determined in certain muscle groups in expe-
rimental animals [30,31], but there are no reliable data on the
turnover of myonuclei in the largemuscles of the trunk and limbs
in humans. Most technologies focus on the delivery of the gene
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of targeting to the endogenous muscle stem cell, the satellite cell,
is rarely examined. In the worst case scenario, myonuclear
turnover rate is high and the gene therapy approach fails to target
satellite cells. In that case, the therapeutic effect will necessarily
be transient, as “corrected” myonuclei are replaced by nuclei
from satellite cells that do not carry the therapeutic vector.
However, examples of both viral and non-viral vectors capable
of transducing satellite cells after intramuscular injections have
been reported [32,33]. Different pseudotyped lentiviral vectors
differentially transduce satellite cells and muscle fibers [33],
thus demonstrating that satellite cells can be specifically
targeted. For non-viral technologies, such targeting would
necessarily involve a carrier that is modified so as to bind
specifically to muscle cells, analogous to methods that have
been proposed for modifying viral vectors to target muscle
[34]. Whether such kinds of modifications could specifically
target satellite cells remains to be determined. The importance
of satellite cell targeting by gene therapy vectors for sustained
therapeutic efficacy may ultimately await empirical determina-
tion in clinical trials or even long-term clinical applications
since studies in animals may poorly reflect the dynamics of
myonuclear turnover in humans.
Solutions to these common challenges will lead to advances
in all aspects of non-viral gene therapy approaches to DMD.
Still, each methodology will also have its “private” hurdles as
well. In the following sections, the different non-viral gene
therapy approaches that are currently under active investigation
for DMD are reviewed, with attention to current challenges and
future directions.
2. Non-viral gene therapy technologies and experimental
therapeutics for DMD
2.1. Plasmid-mediated gene delivery
Plasmid-mediated gene therapy is based on the observation
made over a decade ago that naked plasmid DNA, delivered to
skeletal muscle by direct injection, is taken up in the myofiber
where plasmid genes are expressed [35]. Various parameters
such as plasmid size, concentration, and promoter sequences
have been tested to optimize gene delivery options [36–39].
Advantages of plasmid gene therapy include already existing
scaled-up production processes, applicability to DMD patients
regardless of mutation, and simplicity. Following the initial
observations that dystrophin protein could be expressed in
muscles of mdx mice after simple intramuscular injections of
plasmid [40,41], much effort was devoted to improved efficacy
of distribution, uptake, and expression of injected plasmids.
Improvements have involved adjunctive treatments, notably
using electroporation and ultrasound, co-injecting enzymes
such as hyaluronidase, and using non-ionic carriers for plasmid
DNA [42–48]. Of these, electroporation leads to the most
dramatic enhancement of gene expression, although there is
significant muscle damage that results [49].
Multiple intramuscular injections with electroporation
would, however, be an extremely laborious and invasive methodfor the treatment of all muscles of a patient, not to mention the
challenge of delivering plasmid to the heart and diaphragm by
this method. As such, attention has focused more recently on
regional or systemic delivery of plasmids. Intra-arterial delivery
of plasmid in mdx mice resulted in expression of dystrophin in
1–5% of fibers in the injected limb [13]. This approach has been
used to deliver plasmids to limb muscles in non-human primates
with even higher efficiencies [26].
Given the encouraging results of plasmid-mediated gene
therapy in animals combined with technological advances and
the potential of systemic delivery, this experimental therapeutic
approach has moved from the laboratory to the clinic. A phase I
clinical trial was initiated recently with the overall design of
either a single injection or two injections of plasmid containing
full-length dystrophin cDNA into single muscles of a group of
9 boys with DMD or Becker muscular dystrophy (BMD) [50].
The trial was designed to test for any adverse effects of low
dose intramuscular plasmid injections and for immunological
responses. No adverse effects were noted. In follow up biopsies
3 weeks after injections, dystrophin protein was detected in
only 6 of the 9 boys and in only a small percentage of fibers, but
no signs of an immunological response was observed [51,52].
As clinical trials progress, studies designed to improve the
efficiency and efficacy of plasmid-mediated gene therapy
continue. An unresolved issue for treatment of humans with
DMD is the expected duration of plasmid gene expression. In
mice, transgene expression can be detected for many months
after direct intramuscular injection in normal muscle. However,
there is clearly a continual loss of plasmid over this time [53]. In
humans, sustained expression would be necessary for years and
decades. Therefore, any technological advance that would lead
to plasmid persistence is likely to be an important adjunct to
plasmid-mediated gene therapy for DMD. Recently, a targeted
plasmid integration approach has been used to address this issue
(Fig. 1). This approach is based on the finding that the co-
expression of an integrase with a plasmid that contains one of
the integrase recognition sequences allows for integration of the
plasmid into the mammalian genome [54]. This integrase
technology was applied to the delivery of dystrophin-expressing
plasmids to mdx muscle, and plasmid integration resulted in
more sustained dystrophin expression [55]. An increased
expression of dystrophin was seen at each time point examined,
with the difference increasing with time, demonstrating the
importance of integration for sustained plasmid gene expression
[55]. The integrase-mediated enhancement of long-term gene
expression in skeletal muscle was also evident when tested with
plasmids expressing vascular endothelial growth factor [56].
Ideally, this technology would be truly site-specific,
introducing the dystrophin plasmid into a single site in the
genome, but the currently used integrases clearly integrate at
multiple sites even though there are clear ‘hot spots’ [55,57].
Therefore, there is the theoretical risk of insertional mutagen-
esis, which may have resulted in the development of leukemias
in three patients in a clinical trial of retroviral-mediated gene
therapy for X-linked severe combined immune deficiency [11].
However, not only does recent evidence suggest that those
leukemias may have resulted from expression of the therapeutic
Fig. 1. Targeted plasmid integration to enhance plasmid-mediated gene delivery.
(A) Native function of ϕC31 integrase. This integrase is a phage product that
catalyzes the integration of the phage genome, containing a unique attP
sequence, into the bacterial genome, containing a unique attB sequence. Because
these two sequences are different, the resulting sites following recombination are
distinct (one attL sequence and one attR sequence) and different from the attB
and attP sequences, rendering this reaction unidirectional. (B) Co-opting ϕC31
integrase for gene therapy. By designing plasmids with attB sequences and
delivering a second plasmid encoding the ϕC31 integrase, sites within the
mammalian genome with sufficient sequence homology to attP sites allow for
the integrase to catalyze the recombination and integration of the therapeutic
plasmid into the mammalian genome.
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but this risk is of course very low when postmitotic myonuclei
are the targets as opposed to hematopoietic progenitors.
Finally, an issue that has come to light in studies of plasmid-
mediated gene therapy, even though this would apply to all gene
therapy approaches, is the distribution of the vector and thus the
therapeutic protein along the length of muscle fibers in a targeted
muscle.Many studies of long-term efficacy of plasmid-mediated
gene delivery have been quantitated by measuring the number of
muscle fibers that express the transgene over time [41,59]. This
unfortunately underestimates protein loss; direct comparisons
reveal that the total protein levels can be declining while the
number of fibers that stain positively for the protein remains
relatively constant since fibers with lower, but still detectable,
levels of transgene expression are scored as positive [53]. The
situation is even more critical in dystrophic muscle because of
the issue of segmental necrosis. Any fiber segment that does not
express therapeutic levels of dystrophin is susceptible to
degeneration which can then encroach upon segments with
marginally therapeutic levels. Thus, any fiber in which
dystrophin is not expressed at therapeutic levels along its length
will eventually succumb. This was clear in studies of integrase-
enhancement of plasmid gene therapy where it was found that
the increased dystrophin expression and persistence by integra-
tion results in a higher number of fibers with therapeutic
dystrophin levels along their entire lengths [55]. This findinghighlights the importance of quantifying dystrophin expression
not only in the muscle cross-sections but also along the longi-
tudinal axis of the muscle.
2.2. AON-induced exon skipping
AONs are composed of RNA residues or homologs and have
been primarily used to block translation by binding to mRNA
and leading to its degradation [60]. However, it was also noted
that AONs targeted to splice sites or splicing regulatory regions
of pre-mRNA could alter the splicing of that transcript,
presumably by interfering with the normal splicing machinery
[61]. The rationale for the therapeutic benefit of modifications
of dystrophin transcript splicing to treat DMD is based on the
fact that most cases of DMD are caused by deletions in the
dystrophin gene that lead to frame-shift mutations in the
transcript [62]. Deletions that do not cause a frame shift but
simply an internally deleted protein tend to cause the milder,
allelic disease, BMD. Therefore, it was hypothesized that if one
could alter the splicing of a DMD gene to produce a shorter but
in-frame transcript that this would be a method to convert a
severe DMD phenotype into a milder BMD phenotype (Fig. 2).
Proof-of-principle studies were initially published about a
decade ago [63,64]. Progress was rapid in terms of improved
vector design, target choice, and oligonucleotide chemistries, all
leading to more efficient and effective exon skipping [65–68].
Dystrophin expression was demonstrated using AONs deliv-
ered to dystrophin-deficient muscle cells in vivo in the mdx
mouse or in vitro [69–71]. Further developments toward
clinical application have included methodologies, as mentioned
above, to enhance the uptake of AONs in mouse muscle in vivo
and the use of systemic delivery methods to begin to develop a
clinically feasible delivery approach [17,21–23].
The application of AONs to mediate exon skipping in DMD
has progressed remarkably quickly from the laboratory to the
clinic. Phase I clinical trials with AONs in humans are in early
stages in Britain and Holland [72]. These will involve intra-
muscular injections of AONs to test for safety, and it is likely that
some measures of efficacy will be included in the analysis. If
these phase I trials demonstrate safety, the challenge will be to
scale those up for targeting large muscles, whole limbs, rela-
tively inaccessible targets like the diaphragm and heart, and
ultimately the entire body musculature. It will be at that point
that the translation of systemic delivery methodologies from
laboratory animals to humans will be the major challenge.
At the same time, the development of new generations of
AONs could further enhance therapeutic efficacy. Currently, the
chemistries that are being tested are 2′O-methyl phosphor-
othioate and morpholino-phosphorodiamidate AONs (Fig. 3).
Other chemistries that have been tested include AONs contain-
ing peptide nucleic acids, locked nucleic acid, and ethylene-
bridged nucleic acid backbones [67,73]. Direct comparisons in
terms of efficacy and toxicity in vivo will be required to
determine the optimal chemistry for clinical trials.
One of the challenges of AON therapy is that it is not a ‘one-
size-fits-all’ approach in the same way that gene delivery is. In
order for an AON approach to be applicable, there needs to be an
Fig. 2. Molecular mechanism of AON-induced exon skipping to convert a Duchenne phenotype into a Becker phenotype. The nonsense mutation of the mdx mouse is
shown as an example, but the same principles apply for deletions that generate out-of-frame transcripts in which skipping one or more exons can generate an in-frame
transcript. An AON targeted to exonic splice enhancer sequences is shown. AONs targeted to 5′ or 3′ splice sites are also effective in inducing skipping of the specific
exon.
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more exons to produce an in-frame transcript, evidence that
targeting AONs to specific sequences will result in the desired
transcript, and finally the design of AON vectors specifically for
that particular mutation. This seemingly major hurdle of
customized therapy is partially obviated by the fact there areFig. 3. Chemical structures of modified bases used in AON design. The two
chemical structures shown are the most widely studied and are the modifications
that have been proposed to be tested in human clinical trials.certain deletions that are very common and that a relatively small
number of deletions represent a majority of cases of DMD. Thus,
a limited number of AONs will theoretically be effective in a
majority of DMD patients [74]. In those cases where skipping of
two exons would be necessary to generate an in-frame transcript,
multiple AON delivery could be used, as has been demonstrated
[75]. Of course, without a defined molecular diagnosis, AON
therapy is not applicable.
Finally, one of the intrinsic limitations of AON-mediated
exon skipping is the fact that the therapeutic effect is transient.
AONs are delivered as oligonucleotides which are unstable in
the cell. In mice, detectable levels of dystrophin expression
were obtained by sequential AON injections, but levels declined
with a half-life of approximately 2–4 months [22], and this
could even be an overestimate of AON stability as it may be
more of a reflection of dystrophin protein stability. Even so,
protein persistence is the key determinant of the duration of
therapeutic efficacy and is thus the meaningful measure. As
currently configured, this would mean that AON therapy would
require multiple treatments each year. While not untenable, this
is clearly a serious hurdle to overcome. In mice, investigators
have combined AON technology with viral expression
Fig. 4. Molecular mechanism of ODN-mediated gene editing. A hypothetical
T–A base pair mutation, for which the wild-type pair is a G–C, is illustrated.
The targeting ODN, perfectly complementary to a region of one strand of the
gene of interest except for a single mismatch with the mutant base, is first
involved in a pairing reaction in which the ODN inserts into the double helical
structure. The mismatch between the ODN and the genomic sequence induces
endogenous repair mechanisms to correct the mismatch, and the therapeutic
effect occurs when the genomic base is altered. Following dissociation of the
ODN, the reannealing of the double strand leads to another mismatch. Again,
the therapeutic effect occurs when the mutant base is now corrected, leading to a
permanent conversion of the mutant T–A pair to the wild-type G–C pair.
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and long-term exon skipping [76–78]. However, this introduces
the challenges of viral gene therapy, and there is no clear
advantage of delivering an antisense vector as opposed to
delivering a dystrophin construct itself. Another possibility on
the horizon is to introduce a short cDNA encoding U7-small
nuclear RNA to achieve sustained exon skipping [79]. Thus, the
technological advances that will be critical for long-term AON
therapy will come in the form of oligonucleotide modification
or formulation that promotes very long-term stability or
sustained in vivo delivery.
2.3. Oligonucleotide-mediated genome editing
The use of targeting oligonucleotides to induce single base
changes in genomic DNA developed from initial studies in
homologous pairing and repair activities in bacteria and simple
eukaryotes [80,81]. The theoretical basis for this approach is that
engineered mismatches between the targeting vector and the
genome sequence could, through endogenous DNA repair
mechanisms, potentially promote targeted single base pair
changes in genomic DNA [82–85]. The possibility that such
genome editing potential could be applied to the correction of
point mutations that cause disease was compelling (Fig. 4). As
such, this technology has been applied to a wide variety of
models of diseases arising from point mutations in different
genes [86–88].
Upwards of 15% of patients with DMD have point mutations
as the cause of dystrophin deficiency [4]. Fortuitously for this
particular application, the most commonly used animal model of
DMD, the mdx mouse, also has a point mutation that results in a
stop codon as the cause of dystrophin deficiency. Therefore, the
mdx mouse has served as an excellent model with which to test
oligonucleotide-mediated dystrophin gene editing. Initial stu-
dies using RDOs and subsequent studies using ODNs demon-
strated that the point mutation in the mdx dystrophin gene can
indeed be corrected by targeting oligonucleotides [32,89,90].
Correction was demonstrated at the genomic and transcript
levels, and restoration of dystrophin protein expression was ob-
served both in vivo and in vitro. In addition, RDOs were shown
to be able to correct the point mutation in a canine model of
DMD [91].
The application of this type of technology to diseases that
result from point mutations is clear, but broader applications
have been envisioned whereby single bases in splice sites could
be altered at the genomic level, thereby inducing alternate
splicing to effect the same result as that achieved by AONs,
namely the generation of an in-frame transcript from an out-of-
frame transcript. This approach has been demonstrated in the
mdx mouse by inducing skipping of the exon that contains the
point mutation [92]. As described for AONs, oligonucleotide-
mediated gene editing also requires individualization since the
targeted base will depend on the location of the point mutation or
the particular splice site to be targeted.
Other than the challenges common to all non-viral method-
ologies discussed in Introduction, the major challenge for
oligonucleotide-mediated gene editing is the low efficiency ofthis technology with current vectors that has been observed a
variety of different disease applications [86,87]. The was the
case with the first generation RDO vectors, but has also been
found with the second generation vectors, the ODNs, which
yield more consistent results [85,93]. Both RDOs and ODNs
have been shown to be effective in vitro and in vivo to induce
single base changes, but the efficiencies have generally been in
the 1–5% range, with higher efficiencies being observed only
under specific conditions [86,89,90,92,94–99]. Therefore,
current research is focusing on the enhancement of the molecular
mechanisms that mediate the gene editing, and these studies
include both modifications of the oligonucleotides as well as
enzyme systems and cellular processes involved in the repair
mechanism [100–102]. Improvements in genome editing
efficiency is currently the most important hurdle for the
269T.A. Rando / Biochimica et Biophysica Acta 1772 (2007) 263–271consideration of a phase I clinical trial of ODNs in humans
similar to those conducted or planned for plasmids and AONs.
Perhaps the greatest advantage of the gene editing
approach is that it results in a permanent correction of the
genetic defect in myonuclei. Therefore, the therapeutic benefit
is sustained as long as the targeted myonuclei persist. The
only decrement of therapeutic efficacy is that which would
accompany the turnover of myonuclei and replacement by
nuclei derived from satellite cells, as noted in Introduction.
However, it is possible that even this could be less of an issue
for oligonucleotide-mediated gene editing than for non-viral
methodologies. Although not quantitative, it was shown that
targeting oligonucleotides injected into skeletal muscles of
mdx mice were capable of inducing gene correction in
satellite cells subsequently isolated from those muscles [32].
To the extent that ODNs could be directed both to satellite
cells as well as to myofibers, long-term permanent gene
correction could be achieved.
3. Conclusions
Although the field of gene therapy has failed to live up to
initial promise, the advances in the control of gene expression,
delivery technologies for different vectors, and methods to
avoid, reduce, or prevent immunologic responses to vectors
and therapeutic proteins have benefited all aspects of gene
therapy for all disease for which gene therapy is a viable
option. Clearly, the simplicity of concept belies the complexity
of application. It is likely that, even with the real possibility of
finding a cure for DMD, advances are likely to be incremental.
In the field of non-viral gene therapy for DMD, what is perhaps
most remarkable is the rapid development of technologies that
were little more than curiosities a decade ago. This is an
important lesson for nascent technologies, including other
forms of non-viral gene therapy that have yet to be applied to
models of DMD, that are far behind other methodologies in
terms of technical development. Unless relatively obscure
technologies had been championed by dedicated investigators,
the current state-of-the-art would be much more limited in
scope. It is impossible to predict which curiosity of today will
be in clinical trials a decade hence, and the lessons learned
from the technological development in one area are likely to be
of benefit to the broader field of gene therapy.
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